

IN THE CLAIMS:

Please cancel claims 2-48 without prejudice or disclaimer.

Please amend Claim 1 to read:

*5/26*  
~~1. A method [for treating or detecting in a patient rapidly growing cells of exogenous origin that preferentially accumulate a photoactivatable porphyrin] of treatment comprising [the steps of] administering to [said] a patient, [or contacting said cells, with an] who is suffering from a disorder associated with an agent of exogenous origin, a therapeutically effective amount of a precursor of protoporphyrin IX, and thereafter exposing [said cells] the agent or cell to light capable of photoactivating [said protoporphyrin IX] the porphyrin.~~

*Rule 126* *2* Please also add the following new claims:

*11*  
*--46.* A method according to claim 1, wherein said disorder is characterized by the presence of lesions or cellular abnormalities.

*12* *56.* A method according to claim *46*, wherein said lesions or cellular abnormalities are of epithelial or endothelial origin.

*13* 51. A method according to claim 50, wherein said lesions or cellular abnormalities are of a tissue origin selected from the group consisting of the skin, circulatory system, conjunctiva, parietal pleura, visceral pleura, dura mater meninges, tissues containing abnormal cells, suspensions of body fluids containing abnormal cells, and blood.

*14* 52. A method according to claim 50, wherein said lesions or cellular abnormalities are found in the lining of the group consisting of the mouth, pharynx, esophagus, stomach, intestines, intestinal appendages, rectum, anal canal, nasal passages, nasal sinuses, nasopharynx, trachea, bronchi, and bronchioles, ureters, urinary bladder, urethra, vagina, uterine cervix, uterus, peritoneal cavity, pelvic cavity, surface of the organs contained within the peritoneal cavity, and surface of the organs contained within the pelvic cavity

*15* 53. A method according to claim 1, wherein said agent is an infectious agent.

*16* 54. A method according to claim 1, wherein said agent is bacterial.

*17* 55. A method according to claim 1, wherein said agent is viral.

*18* 56. A method according to claim 1, wherein said agent is fungal.

what does this claim mean? anti-fungal?

*Sub Obj* 19 57. A method of treatment, comprising administering to a patient, who is suffering from a disorder caused by an agent of exogenous origin, a therapeutically effective amount of a precursor of protoporphyrin IX, and thereafter exposing said patient to light capable of photoactivating protoporphyrin IX.

20 58. A method according to claim 57, wherein said disorder is characterized by the presence of lesions or cellular abnormalities.

21 59. A method according to claim 58, wherein said lesions or cellular abnormalities are of epithelial or endothelial origin.

22 60. A method according to claim 59, wherein said lesions or cellular abnormalities are of a tissue origin selected from the group consisting of the skin, circulatory system, conjunctiva, parietal pleura, visceral pleura, dura mater meninges, tissues containing abnormal cells, suspensions of body fluids containing abnormal cells, and blood.

23 61. A method according to claim 59, wherein said lesions or cellular abnormalities are found in the lining of the group consisting of the mouth, pharynx, esophagus, stomach, intestines, intestinal appendages, rectum, anal canal, nasal passages, nasal sinuses, nasopharynx, trachea, bronchi, and bronchioles, ureters, urinary bladder, urethra, vagina, uterine cervix, uterus, peritoneal cavity, pelvic cavity, surface of the organs contained within the peritoneal cavity, and surface of the organs contained within the pelvic cavity

*Sub E 2 cont* 24 62. A method according to claim 57, wherein said agent is an infectious agent. *19*

*Sub E 2 cont* 25 63. A method according to claim 57, wherein said agent is bacterial. *19*

*Sub E 2 cont* 26 64. A method according to claim 57, wherein said agent is viral. *19*

*Sub E 2 cont* 27 65. A method according to claim 57, wherein said agent is fungal. *19*

*Sub E 2 cont* 28 66. A method according to claim 1, wherein the precursor of protoporphyrin IX is 5-aminolevulinic acid. *19*

*Sub E 2 cont* 29 67. A method according to claim 57, wherein the precursor of protoporphyrin IX is 5-aminolevulinic acid. -- *19*

REMARKS

Entry of the foregoing amendments prior to examination is respectfully requested.

Respectfully submitted,



Reg. No. 42,822

for Sybil Meloy  
Reg. No. 22,749

April 19, 1999

FOLEY & LARDNER  
3000 K Street, N.W.  
Suite 500  
Washington, D.C. 20007-5109  
Tel: (202) 672-5300